Inducing and exploiting vulnerabilities for the treatment of liver cancer

Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies 1 , 2 ; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma 3 . The induction of senescence may represent a strategy for the t...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Nature (London) Ročník 574; číslo 7777; s. 268 - 272
Hlavní autori: Wang, Cun, Vegna, Serena, Jin, Haojie, Benedict, Bente, Lieftink, Cor, Ramirez, Christel, de Oliveira, Rodrigo Leite, Morris, Ben, Gadiot, Jules, Wang, Wei, du Chatinier, Aimée, Wang, Liqin, Gao, Dongmei, Evers, Bastiaan, Jin, Guangzhi, Xue, Zheng, Schepers, Arnout, Jochems, Fleur, Sanchez, Antonio Mulero, Mainardi, Sara, te Riele, Hein, Beijersbergen, Roderick L., Qin, Wenxin, Akkari, Leila, Bernards, René
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London Nature Publishing Group UK 01.10.2019
Nature Publishing Group
Predmet:
ISSN:0028-0836, 1476-4687, 1476-4687
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies 1 , 2 ; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma 3 . The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis) 4 , 5 . Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53 . A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition 6 is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer. CDC7 inhibition selectively induces senescence in hepatocellular carcinoma cells with TP53 mutations, which enables the selective apoptotic cell death of these senescent cells using inhibitors of mTOR signalling.
AbstractList Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies ; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma . The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis) . Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.
Liver cancer remains difficult to treat due to a paucity of drugs that target critical dependencies1,2 and broad spectrum kinase inhibitors like sorafenib provide only modest benefit to hepatocellular carcinoma (HCC) patients3. Induction of senescence may represent a promising strategy for the treatment of cancer, especially when such pro-senescence therapy is combined with a second drug that selectively eliminates senescent cancer cells (senolysis)4,5. Through a kinome-focused genetic screen, we report here that pharmacological inhibition of the DNA replication kinase CDC7 induces senescence selectively in TP53 mutant liver cancer cells. A follow-up chemical screen identified the anti-depressant sertraline as an agent that kills HCC cells rendered senescent by CDC7 inhibition. Sertraline supressed mTOR signalling, and selective drugs targeting this pathway were highly effective in causing apoptotic cell death of CDC7 inhibitor-treated HCC cells. Mechanistically, we report that the feedback re-activation of mTOR signalling following its inhibition6 is blocked in CDC7-inhibitor treated cells, leading to sustained mTOR inhibition and cell death. Using multiple in vivo liver cancer models, we show that combination of CDC7 and mTOR inhibitors results in dramatic tumour growth inhibition. More generally, our data indicate that exploiting an induced vulnerability could be an effective treatment of liver cancer.
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies 1 , 2 ; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma 3 . The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis) 4 , 5 . Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53 . A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition 6 is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer. CDC7 inhibition selectively induces senescence in hepatocellular carcinoma cells with TP53 mutations, which enables the selective apoptotic cell death of these senescent cells using inhibitors of mTOR signalling.
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies.sup.1,2; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma.sup.3. The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis).sup.4,5. Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition.sup.6 is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma. The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis). Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies.sup.1,2; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma.sup.3. The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis).sup.4,5. Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition.sup.6 is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer. CDC7 inhibition selectively induces senescence in hepatocellular carcinoma cells with TP53 mutations, which enables the selective apoptotic cell death of these senescent cells using inhibitors of mTOR signalling.
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies1,2; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma3. The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis)4,5. Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition6 is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies1,2; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma3. The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis)4,5. Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition6 is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.
Audience Academic
Author Sanchez, Antonio Mulero
Jochems, Fleur
Morris, Ben
Beijersbergen, Roderick L.
Wang, Wei
Vegna, Serena
de Oliveira, Rodrigo Leite
Mainardi, Sara
Bernards, René
Qin, Wenxin
Gao, Dongmei
Wang, Cun
Xue, Zheng
Evers, Bastiaan
Lieftink, Cor
du Chatinier, Aimée
Benedict, Bente
Gadiot, Jules
Jin, Guangzhi
Akkari, Leila
Jin, Haojie
Wang, Liqin
te Riele, Hein
Ramirez, Christel
Schepers, Arnout
AuthorAffiliation 2 Division of Molecular Carcinogenesis, Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
1 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
3 Division of Tumour Biology and Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
4 Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
5 Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China
AuthorAffiliation_xml – name: 5 Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China
– name: 6 Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
– name: 2 Division of Molecular Carcinogenesis, Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
– name: 3 Division of Tumour Biology and Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
– name: 1 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
– name: 4 Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Author_xml – sequence: 1
  givenname: Cun
  surname: Wang
  fullname: Wang, Cun
  organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 2
  givenname: Serena
  surname: Vegna
  fullname: Vegna, Serena
  organization: Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute
– sequence: 3
  givenname: Haojie
  surname: Jin
  fullname: Jin, Haojie
  organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 4
  givenname: Bente
  surname: Benedict
  fullname: Benedict, Bente
  organization: Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute
– sequence: 5
  givenname: Cor
  surname: Lieftink
  fullname: Lieftink, Cor
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 6
  givenname: Christel
  surname: Ramirez
  fullname: Ramirez, Christel
  organization: Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute
– sequence: 7
  givenname: Rodrigo Leite
  surname: de Oliveira
  fullname: de Oliveira, Rodrigo Leite
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 8
  givenname: Ben
  surname: Morris
  fullname: Morris, Ben
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 9
  givenname: Jules
  surname: Gadiot
  fullname: Gadiot, Jules
  organization: Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute
– sequence: 10
  givenname: Wei
  surname: Wang
  fullname: Wang, Wei
  organization: Division of Cell Biology, The Netherlands Cancer Institute
– sequence: 11
  givenname: Aimée
  surname: du Chatinier
  fullname: du Chatinier, Aimée
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 12
  givenname: Liqin
  surname: Wang
  fullname: Wang, Liqin
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 13
  givenname: Dongmei
  surname: Gao
  fullname: Gao, Dongmei
  organization: Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education
– sequence: 14
  givenname: Bastiaan
  surname: Evers
  fullname: Evers, Bastiaan
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 15
  givenname: Guangzhi
  surname: Jin
  fullname: Jin, Guangzhi
  organization: Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
– sequence: 16
  givenname: Zheng
  surname: Xue
  fullname: Xue, Zheng
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 17
  givenname: Arnout
  surname: Schepers
  fullname: Schepers, Arnout
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 18
  givenname: Fleur
  surname: Jochems
  fullname: Jochems, Fleur
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 19
  givenname: Antonio Mulero
  surname: Sanchez
  fullname: Sanchez, Antonio Mulero
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 20
  givenname: Sara
  surname: Mainardi
  fullname: Mainardi, Sara
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 21
  givenname: Hein
  surname: te Riele
  fullname: te Riele, Hein
  organization: Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute
– sequence: 22
  givenname: Roderick L.
  surname: Beijersbergen
  fullname: Beijersbergen, Roderick L.
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
– sequence: 23
  givenname: Wenxin
  surname: Qin
  fullname: Qin, Wenxin
  email: wxqin@sjtu.edu.cn
  organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine
– sequence: 24
  givenname: Leila
  surname: Akkari
  fullname: Akkari, Leila
  email: l.akkari@nki.nl
  organization: Oncode Institute, Division of Tumour Biology and Immunology, The Netherlands Cancer Institute
– sequence: 25
  givenname: René
  surname: Bernards
  fullname: Bernards, René
  email: r.bernards@nki.nl
  organization: Oncode Institute, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31578521$$D View this record in MEDLINE/PubMed
BookMark eNp9kktr3DAUhU1JaSZpf0A3xbSbdOFUD1uWN4EQmnYgUOhjLWT5ylHQSBNJHtJ_X5lJmkyYFi-MrO8cWeeeo-LAeQdF8RajU4wo_xRr3HBWIdxVmKG2oi-KBa5bVtWMtwfFAiHCK8QpOyyOYrxBCDW4rV8VhxQ3LW8IXhTLpRsmZdxYSjeUcLe23qR5uZmsgyB7Y_MaYql9KNM1lCmATCtwqfS6tGYDoVTSKQivi5da2ghv7t_Hxa_Lzz8vvlZX374sL86vKsU6lipMZdPxGuuu14oS0iupe0olAt7XRA98YKoeeuCsxYA4hmEgqENMNlrLRmJ6XJxtfddTv4JB5V8J0op1MCsZfgsvjdjdceZajH4jGG8453U2OLk3CP52gpjEykQF1koHfoqC0JxTxzlpM_rhGXrjp-Dy9WaK1S1hDXmkRmlBGKd9PlfNpuKc0TYPgJD52GoPNcKcss1z1SZ_3uHf7-HV2tyKp9DpHig_A6yM2uv6cUeQmQR3aZRTjGL54_su--5p0n8jfmhPBtotoIKPMYAWyiSZjJ-DN1ZgJOaeim1PRe6pmHsqaFbiZ8oH8_9pyFYTM-tGCI_D-LfoD3w09uQ
CitedBy_id crossref_primary_10_1016_j_compbiomed_2024_109196
crossref_primary_10_1016_j_devcel_2023_05_010
crossref_primary_10_1038_s41467_021_25700_6
crossref_primary_10_33590_emjhepatol_QCRI8208
crossref_primary_10_1016_j_semcancer_2024_05_002
crossref_primary_10_1158_1535_7163_MCT_24_0949
crossref_primary_10_1038_s41586_025_08585_z
crossref_primary_10_1053_j_gastro_2023_05_029
crossref_primary_10_3389_fonc_2022_978050
crossref_primary_10_1093_bib_bbaa164
crossref_primary_10_4155_ppa_2022_0043
crossref_primary_10_7554_eLife_76294
crossref_primary_10_1007_s12672_025_02885_6
crossref_primary_10_1146_annurev_cancerbio_061421_124434
crossref_primary_10_3390_cancers14112745
crossref_primary_10_1038_s41388_020_1354_9
crossref_primary_10_3390_ijms241512509
crossref_primary_10_1186_s12943_021_01466_9
crossref_primary_10_1016_j_bcp_2021_114765
crossref_primary_10_1016_j_jhep_2025_08_021
crossref_primary_10_1016_j_phrs_2020_105071
crossref_primary_10_1124_molpharm_124_000871
crossref_primary_10_1016_j_tice_2025_103089
crossref_primary_10_1038_s41388_022_02291_0
crossref_primary_10_1080_15384101_2021_1986999
crossref_primary_10_1158_0008_5472_CAN_20_1811
crossref_primary_10_1155_2022_7609676
crossref_primary_10_3389_fphys_2021_702276
crossref_primary_10_1002_advs_202308310
crossref_primary_10_1007_s10529_024_03491_2
crossref_primary_10_1038_s41575_021_00465_x
crossref_primary_10_1002_mco2_695
crossref_primary_10_1038_s41698_023_00375_y
crossref_primary_10_1007_s00281_021_00861_0
crossref_primary_10_3390_cancers16244239
crossref_primary_10_1007_s44272_024_00027_7
crossref_primary_10_1097_HC9_0000000000000101
crossref_primary_10_3390_cells9122540
crossref_primary_10_1002_advs_202206798
crossref_primary_10_3389_fonc_2025_1584811
crossref_primary_10_1111_jcmm_15693
crossref_primary_10_3390_ijms22052623
crossref_primary_10_1038_s41565_024_01690_6
crossref_primary_10_1158_0008_5472_CAN_23_0673
crossref_primary_10_1016_j_cell_2024_05_059
crossref_primary_10_1002_tox_24121
crossref_primary_10_1016_j_biopha_2023_116099
crossref_primary_10_1038_s42003_021_02257_0
crossref_primary_10_1073_pnas_2018229118
crossref_primary_10_1093_jb_mvaf001
crossref_primary_10_1016_j_tranon_2021_101303
crossref_primary_10_1111_1440_1681_13528
crossref_primary_10_1038_s41392_024_01823_2
crossref_primary_10_1093_bib_bbaa295
crossref_primary_10_3389_fcell_2022_861000
crossref_primary_10_3390_cancers17121941
crossref_primary_10_1016_S0140_6736_22_01200_4
crossref_primary_10_1109_TCBB_2020_3004808
crossref_primary_10_1016_j_engappai_2024_108289
crossref_primary_10_1371_journal_pone_0273182
crossref_primary_10_1039_D0SC01234C
crossref_primary_10_1186_s40537_023_00752_1
crossref_primary_10_3389_fonc_2025_1580951
crossref_primary_10_1002_1878_0261_12761
crossref_primary_10_1016_j_bbrc_2021_09_009
crossref_primary_10_1158_0008_5472_CAN_21_2032
crossref_primary_10_1016_j_ccell_2025_05_015
crossref_primary_10_1038_s41419_024_06427_w
crossref_primary_10_1111_pin_13403
crossref_primary_10_1038_s41420_023_01571_2
crossref_primary_10_1038_s41571_022_00668_4
crossref_primary_10_1002_ctd2_262
crossref_primary_10_15252_embr_202154275
crossref_primary_10_3389_fonc_2023_1189015
crossref_primary_10_15252_emmm_202114876
crossref_primary_10_1038_s41590_024_01988_6
crossref_primary_10_1158_0008_5472_CAN_23_1749
crossref_primary_10_3390_curroncol32080467
crossref_primary_10_1016_j_bbcan_2020_188378
crossref_primary_10_1016_j_molcel_2020_05_031
crossref_primary_10_1093_jb_mvae091
crossref_primary_10_2174_0929867327999200820124111
crossref_primary_10_1038_s41420_025_02379_y
crossref_primary_10_1002_cac2_12591
crossref_primary_10_1016_j_ijbiomac_2024_139073
crossref_primary_10_3389_fonc_2021_659963
crossref_primary_10_3390_biom13071085
crossref_primary_10_1038_s41568_022_00450_9
crossref_primary_10_1098_rsob_200148
crossref_primary_10_1007_s00018_021_03798_7
crossref_primary_10_1002_mog2_70007
crossref_primary_10_3390_cells12010132
crossref_primary_10_3390_cancers13184732
crossref_primary_10_1002_path_6065
crossref_primary_10_1007_s10555_023_10089_z
crossref_primary_10_1038_s41587_020_00750_1
crossref_primary_10_1136_gutjnl_2019_319780
crossref_primary_10_1016_j_mad_2025_112040
crossref_primary_10_1002_cbic_202400105
crossref_primary_10_1038_s44321_025_00296_2
crossref_primary_10_3390_biomedicines12010026
crossref_primary_10_1158_2159_8290_CD_22_0244
crossref_primary_10_1016_j_imbio_2024_152841
crossref_primary_10_1097_MS9_0000000000002074
crossref_primary_10_3390_cells14151181
crossref_primary_10_1186_s13046_023_02855_2
crossref_primary_10_1016_j_canlet_2025_217514
crossref_primary_10_1186_s13073_021_00981_0
crossref_primary_10_3390_ijms232213715
crossref_primary_10_32604_oncologie_2021_014152
crossref_primary_10_1111_febs_17127
crossref_primary_10_1177_1934578X221102032
crossref_primary_10_1038_s41422_020_0348_z
crossref_primary_10_1053_j_gastro_2024_01_025
crossref_primary_10_1080_02648725_2023_2193776
crossref_primary_10_1038_s41556_020_0511_2
crossref_primary_10_1038_s43018_020_0067_x
crossref_primary_10_3390_cells9020346
crossref_primary_10_1002_jev2_12154
crossref_primary_10_3390_cells9071593
crossref_primary_10_1007_s10238_025_01556_8
crossref_primary_10_1186_s13045_024_01526_9
crossref_primary_10_1002_1878_0261_13042
crossref_primary_10_1097_MD_0000000000023197
crossref_primary_10_3390_md22030114
crossref_primary_10_1016_j_semcancer_2021_11_004
crossref_primary_10_1093_jnci_djab064
crossref_primary_10_1038_s41575_020_0262_3
crossref_primary_10_1002_advs_202403782
crossref_primary_10_1016_j_biopha_2022_113566
crossref_primary_10_1002_mog2_70029
crossref_primary_10_1016_j_ccell_2021_03_010
crossref_primary_10_1016_j_canlet_2025_217530
crossref_primary_10_1016_j_semcancer_2022_02_005
crossref_primary_10_1016_j_ccell_2023_06_007
crossref_primary_10_1016_j_trecan_2024_11_010
crossref_primary_10_3390_ijms231911082
crossref_primary_10_1038_s41467_024_54072_w
crossref_primary_10_1038_s43018_023_00671_3
crossref_primary_10_3389_fcell_2023_1220376
crossref_primary_10_1038_s41420_023_01777_4
crossref_primary_10_1016_j_ejphar_2024_176493
crossref_primary_10_1093_nar_gkac545
crossref_primary_10_1002_1878_0261_13377
crossref_primary_10_1016_j_canlet_2021_07_002
crossref_primary_10_1038_s41568_024_00737_z
crossref_primary_10_1186_s12957_024_03364_y
crossref_primary_10_3389_fonc_2022_897804
crossref_primary_10_1016_j_tcb_2020_07_002
crossref_primary_10_1038_s43018_022_00462_2
crossref_primary_10_1038_s41571_024_00966_z
crossref_primary_10_1158_2159_8290_CD_20_1187
crossref_primary_10_1016_j_bcp_2024_116385
crossref_primary_10_1007_s13402_024_00967_1
crossref_primary_10_3389_fphar_2024_1422033
crossref_primary_10_1097_MD_0000000000021993
crossref_primary_10_1038_s41571_023_00815_5
crossref_primary_10_1002_adma_202100472
crossref_primary_10_1038_s41568_025_00840_9
crossref_primary_10_1016_j_jhep_2020_01_019
crossref_primary_10_1016_j_canlet_2020_02_016
crossref_primary_10_1007_s12032_023_02250_z
crossref_primary_10_1016_j_lfs_2024_122631
crossref_primary_10_3390_cells13151281
crossref_primary_10_1038_s41421_023_00529_z
crossref_primary_10_1101_gad_343129_120
crossref_primary_10_1016_j_jep_2021_114553
crossref_primary_10_3390_ijms23084168
crossref_primary_10_1007_s10495_024_02042_4
crossref_primary_10_1016_j_ejmech_2025_117491
crossref_primary_10_1055_s_0040_1722262
crossref_primary_10_1016_j_jare_2024_04_007
crossref_primary_10_1158_2159_8290_CD_22_0405
crossref_primary_10_3389_fimmu_2024_1375730
crossref_primary_10_1007_s11427_019_1629_6
crossref_primary_10_1038_s43587_025_00886_2
crossref_primary_10_3389_fgene_2022_874805
crossref_primary_10_1002_mnfr_201901231
crossref_primary_10_1038_s41392_021_00775_1
crossref_primary_10_3390_ijms21041266
crossref_primary_10_3390_cancers12092498
crossref_primary_10_1016_j_cca_2020_03_024
crossref_primary_10_1038_s41598_021_93055_5
crossref_primary_10_1016_j_xphs_2022_06_015
crossref_primary_10_1038_s41568_023_00576_4
crossref_primary_10_1016_j_cclet_2022_07_009
crossref_primary_10_1002_SMMD_20230005
crossref_primary_10_1038_s41467_023_43274_3
crossref_primary_10_3390_cells12060860
crossref_primary_10_1016_j_colsurfa_2025_137757
crossref_primary_10_1038_s41368_025_00380_w
crossref_primary_10_1038_s41586_022_04698_x
crossref_primary_10_1002_ange_202101278
crossref_primary_10_1002_advs_202100759
crossref_primary_10_1016_j_jare_2024_08_034
crossref_primary_10_3390_diagnostics12030609
crossref_primary_10_1016_j_ebiom_2022_104397
crossref_primary_10_1016_j_bcp_2022_114989
crossref_primary_10_1155_2022_5705896
crossref_primary_10_1002_app_56262
crossref_primary_10_1038_s41586_020_2403_9
crossref_primary_10_1002_cac2_12374
crossref_primary_10_1016_j_phrs_2024_107198
crossref_primary_10_1186_s12935_023_02949_z
crossref_primary_10_1016_j_cclet_2024_109681
crossref_primary_10_1155_2022_2313416
crossref_primary_10_1038_s41575_022_00704_9
crossref_primary_10_3389_fonc_2020_589908
crossref_primary_10_1038_s41467_024_46835_2
crossref_primary_10_1186_s13046_020_01603_0
crossref_primary_10_3389_fonc_2022_942341
crossref_primary_10_1016_j_bcp_2022_115021
crossref_primary_10_1016_j_snb_2022_131618
crossref_primary_10_1038_s41380_025_03118_6
crossref_primary_10_1039_D1SC04162B
crossref_primary_10_3389_fendo_2022_1061091
crossref_primary_10_1016_j_taap_2020_115259
crossref_primary_10_1038_s41419_022_05229_2
crossref_primary_10_1002_ctm2_1418
crossref_primary_10_3390_biomedicines13040948
crossref_primary_10_1158_1541_7786_MCR_21_0029
crossref_primary_10_1016_j_cmet_2022_11_001
crossref_primary_10_1158_2159_8290_CD_20_1657
crossref_primary_10_1016_j_bbamcr_2021_119048
crossref_primary_10_1158_1541_7786_MCR_21_0146
crossref_primary_10_1007_s00018_020_03746_x
crossref_primary_10_1016_j_snb_2020_128302
crossref_primary_10_1002_1878_0261_12916
crossref_primary_10_1002_prp2_70168
crossref_primary_10_1097_MD_0000000000034365
crossref_primary_10_1098_rsob_220171
crossref_primary_10_1007_s10522_025_10200_7
crossref_primary_10_1016_j_cmet_2024_03_009
crossref_primary_10_1016_j_intimp_2022_108866
crossref_primary_10_1002_mco2_542
crossref_primary_10_1631_jzus_B2200178
crossref_primary_10_1111_cas_16184
crossref_primary_10_3389_fmolb_2021_766609
crossref_primary_10_3390_ijms25158448
crossref_primary_10_1002_1878_0261_13582
crossref_primary_10_1002_mdc3_14266
crossref_primary_10_1007_s11696_021_01509_x
crossref_primary_10_1016_j_biomaterials_2025_123355
crossref_primary_10_1038_s41575_024_00913_4
crossref_primary_10_1016_j_celrep_2024_114818
crossref_primary_10_1007_s13258_024_01515_9
crossref_primary_10_1016_j_cell_2023_02_020
crossref_primary_10_1016_j_ymthe_2020_08_011
crossref_primary_10_3389_fimmu_2022_740805
crossref_primary_10_1007_s12094_022_02853_4
crossref_primary_10_1016_j_taap_2022_116231
crossref_primary_10_1038_s41467_024_45421_w
crossref_primary_10_1002_anie_202101278
crossref_primary_10_3389_fphar_2024_1422363
crossref_primary_10_1007_s12672_025_02182_2
crossref_primary_10_3390_molecules29235652
crossref_primary_10_1016_j_semcancer_2024_10_006
crossref_primary_10_3390_nu14173636
crossref_primary_10_1186_s12967_023_04704_4
crossref_primary_10_3390_cimb47070558
crossref_primary_10_1016_j_semcancer_2020_12_010
crossref_primary_10_1007_s13402_024_01018_5
crossref_primary_10_3390_cancers13051118
crossref_primary_10_1038_s41388_024_03142_w
crossref_primary_10_1038_s41580_021_00404_3
crossref_primary_10_1186_s13045_023_01426_4
crossref_primary_10_1265_ehpm_24_00139
crossref_primary_10_3389_fphar_2022_829759
crossref_primary_10_1016_j_ygeno_2021_02_017
crossref_primary_10_2147_CMAR_S285083
crossref_primary_10_1016_j_semcancer_2021_03_021
crossref_primary_10_1038_s41598_025_96488_4
crossref_primary_10_1021_acs_chemrestox_4c00208
crossref_primary_10_3389_fonc_2023_1110909
crossref_primary_10_1038_s43018_021_00175_y
crossref_primary_10_1038_s41586_021_03741_7
crossref_primary_10_1016_j_tranon_2023_101825
crossref_primary_10_3748_wjg_v30_i40_4380
crossref_primary_10_1007_s13402_025_01075_4
crossref_primary_10_1002_mco2_70048
crossref_primary_10_1016_j_aca_2020_07_079
crossref_primary_10_3389_fonc_2020_579464
crossref_primary_10_1016_j_tdr_2025_100034
crossref_primary_10_3389_fcell_2024_1368711
crossref_primary_10_1093_lifemeta_loae016
crossref_primary_10_1097_MD_0000000000042886
crossref_primary_10_1038_s41573_024_01074_4
crossref_primary_10_2147_DDDT_S332847
crossref_primary_10_1002_1878_0261_13312
crossref_primary_10_1016_j_medj_2021_03_002
crossref_primary_10_1155_2021_5529518
Cites_doi 10.1016/j.bmcl.2012.04.024
10.1016/j.cell.2017.05.046
10.1038/nature25167
10.1111/his.13528
10.1002/hep.30337
10.1016/j.ccell.2016.09.003
10.3322/caac.21492
10.1053/j.gastro.2015.05.061
10.1038/nbt.1526
10.1056/NEJMoa0708857
10.1038/nbt.3536
10.1158/0008-5472.CAN-09-4072
10.1038/onc.2008.213
10.1158/2159-8290.CD-11-0085
10.1158/1078-0432.CCR-10-0185
10.1038/nm.4107
10.1016/j.celrep.2017.09.085
10.1038/nprot.2006.5
10.1038/ncomms15691
10.1073/pnas.0506580102
10.1038/nrdp.2016.18
10.1038/nm.4010
10.1038/s41422-018-0020-z
10.1128/MCB.22.15.5575-5584.2002
10.1016/j.tcb.2018.04.006
10.1038/s41568-019-0156-2
10.1016/j.ccell.2018.06.007
10.1021/acs.jmedchem.6b00680
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Nature Limited 2019
COPYRIGHT 2019 Nature Publishing Group
Copyright Nature Publishing Group Oct 10, 2019
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Nature Limited 2019
– notice: COPYRIGHT 2019 Nature Publishing Group
– notice: Copyright Nature Publishing Group Oct 10, 2019
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QG
7QL
7QP
7QR
7RV
7SN
7SS
7ST
7T5
7TG
7TK
7TM
7TO
7U9
7X2
7X7
7XB
88A
88E
88G
88I
8AF
8AO
8C1
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
8G5
ABJCF
ABUWG
AEUYN
AFKRA
ARAPS
ATCPS
AZQEC
BBNVY
BEC
BENPR
BGLVJ
BHPHI
BKSAR
C1K
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9.
KB.
KB0
KL.
L6V
LK8
M0K
M0S
M1P
M2M
M2O
M2P
M7N
M7P
M7S
MBDVC
NAPCQ
P5Z
P62
P64
PATMY
PCBAR
PDBOC
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PSYQQ
PTHSS
PYCSY
Q9U
R05
RC3
S0X
SOI
7X8
5PM
DOI 10.1038/s41586-019-1607-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Nursing & Allied Health Database
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Agricultural Science Collection
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
Science Database (Alumni Edition)
STEM Database
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
Materials Science & Engineering Collection
ProQuest Central (Alumni Edition)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Computer Science Collection
Agricultural & Environmental Science Collection
ProQuest Central Essentials
Biological Science Collection
eLibrary
ProQuest Central
ProQuest Technology Collection
Natural Science Collection
Earth, Atmospheric & Aquatic Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Materials Science Database
Nursing & Allied Health Database (Alumni Edition)
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest Engineering Collection
ProQuest Biological Science Collection
Agricultural Science Database
Health & Medical Collection (Alumni Edition)
Medical Database
Psychology Database
ProQuest Research library
Science Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Engineering Database
Research Library (Corporate)
Nursing & Allied Health Premium
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
Environmental Science Database
Earth, Atmospheric & Aquatic Science Database
Materials Science Collection
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
Engineering Collection
Environmental Science Collection
ProQuest Central Basic
University of Michigan
Genetics Abstracts
SIRS Editorial
Environment Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Agricultural Science Database
ProQuest One Psychology
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
elibrary
ProQuest AP Science
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Meteorological & Geoastrophysical Abstracts
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Advanced Technologies & Aerospace Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Earth, Atmospheric & Aquatic Science Database
Agricultural Science Collection
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Science Collection
Entomology Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest One Academic (New)
University of Michigan
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
SIRS Editorial
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
Earth, Atmospheric & Aquatic Science Collection
ProQuest Health & Medical Research Collection
Genetics Abstracts
ProQuest Engineering Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Agricultural & Environmental Science Collection
AIDS and Cancer Research Abstracts
Materials Science Database
ProQuest Research Library
ProQuest Materials Science Collection
ProQuest Public Health
ProQuest Central Basic
ProQuest Science Journals
ProQuest Nursing & Allied Health Source
ProQuest Psychology Journals (Alumni)
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
ProQuest Psychology Journals
Animal Behavior Abstracts
Materials Science & Engineering Collection
Immunology Abstracts
Environment Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE





Agricultural Science Database


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: PATMY
  name: Environmental Science Database
  url: http://search.proquest.com/environmentalscience
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Physics
EISSN 1476-4687
EndPage 272
ExternalDocumentID PMC6858884
A637083224
31578521
10_1038_s41586_019_1607_3
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: European Research Council
  grantid: 787925
GroupedDBID ---
--Z
-DZ
-ET
-~X
.55
.CO
.XZ
07C
0R~
0WA
123
186
1OL
1VR
29M
2KS
2XV
39C
41X
53G
5RE
6TJ
70F
7RV
7X2
7X7
7XC
85S
88A
88E
88I
8AF
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
8G5
8R4
8R5
8WZ
97F
97L
A6W
A7Z
AAEEF
AAHBH
AAHTB
AAIKC
AAKAB
AAMNW
AASDW
AAYEP
AAYZH
AAZLF
ABDQB
ABFSI
ABIVO
ABJCF
ABJNI
ABLJU
ABOCM
ABPEJ
ABPPZ
ABUWG
ABWJO
ABZEH
ACBEA
ACBWK
ACGFO
ACGFS
ACGOD
ACIWK
ACKOT
ACMJI
ACNCT
ACPRK
ACWUS
ADBBV
ADFRT
ADUKH
AENEX
AEUYN
AFBBN
AFFNX
AFKRA
AFLOW
AFRAH
AFSHS
AGAYW
AGHSJ
AGHTU
AGSOS
AHMBA
AHSBF
AIDAL
AIDUJ
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
ARAPS
ARMCB
ASPBG
ATCPS
ATWCN
AVWKF
AXYYD
AZFZN
AZQEC
BBNVY
BCU
BEC
BENPR
BGLVJ
BHPHI
BIN
BKEYQ
BKKNO
BKSAR
BPHCQ
BVXVI
CCPQU
CJ0
CS3
D1I
D1J
D1K
DU5
DWQXO
E.-
E.L
EAP
EBS
EE.
EJD
EMH
EPS
ESX
EX3
EXGXG
F5P
FEDTE
FQGFK
FSGXE
FYUFA
GNUQQ
GUQSH
HCIFZ
HG6
HMCUK
HVGLF
HZ~
I-F
IAO
ICQ
IEA
IEP
IGS
IH2
IHR
INH
INR
IOF
IPY
ISR
ITC
K6-
KB.
KOO
L6V
L7B
LK5
LK8
LSO
M0K
M0L
M1P
M2M
M2O
M2P
M7P
M7R
M7S
N9A
NAPCQ
NEPJS
O9-
OBC
OES
OHH
OMK
OVD
P2P
P62
PATMY
PCBAR
PDBOC
PKN
PQQKQ
PROAC
PSQYO
PSYQQ
PTHSS
PYCSY
Q2X
R05
RND
RNS
RNT
RNTTT
RXW
S0X
SC5
SHXYY
SIXXV
SJFOW
SJN
SNYQT
SOJ
SV3
TAE
TAOOD
TBHMF
TDRGL
TEORI
TN5
TSG
TWZ
U5U
UIG
UKHRP
UKR
UMD
UQL
VQA
VVN
WH7
WOW
X7M
XIH
XKW
XZL
Y6R
YAE
YCJ
YFH
YIF
YIN
YNT
YOC
YQT
YR2
YR5
YXB
YZZ
Z5M
ZCA
ZE2
~02
~7V
~88
~KM
AARCD
AAYXX
ABFSG
ABUFD
ACSTC
ADXHL
AEZWR
AFANA
AFFHD
AFHIU
AGSTI
AHWEU
AIXLP
ALPWD
ATHPR
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
TUS
.-4
.GJ
.HR
00M
08P
1CY
1VW
354
3EH
3O-
4.4
41~
42X
4R4
663
79B
9M8
A8Z
AAJYS
AAKAS
AAVBQ
ABAWZ
ABDBF
ABDPE
ABEFU
ABNNU
ACBNA
ACBTR
ACRPL
ACTDY
ACUHS
ADGHP
ADNMO
ADRHT
ADYSU
ADZCM
AETEA
AFFDN
AFHKK
AGCDD
AGGDT
AGNAY
AGQPQ
AIYXT
AJUXI
APEBS
ARTTT
B0M
BCR
BDKGC
BES
BKOMP
BLC
CGR
CUY
CVF
DB5
DO4
EAD
EAS
EAZ
EBC
EBD
EBO
ECC
ECM
EIF
EMB
EMF
EMK
EMOBN
EPL
ESE
ESN
FA8
FAC
J5H
L-9
LGEZI
LOTEE
MVM
N4W
NADUK
NEJ
NFIDA
NPM
NXXTH
ODYON
OHT
P-O
PEA
PM3
PV9
QS-
R4F
RHI
SKT
TH9
TUD
UBY
UHB
USG
VOH
X7L
XOL
YJ6
YQI
YQJ
YV5
YXA
YYP
YYQ
ZCG
ZGI
ZHY
ZKB
ZY4
~8M
~G0
ACMFV
AEIIB
PMFND
3V.
7QG
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7TG
7TK
7TM
7TO
7U9
7XB
8FD
8FK
C1K
FR3
H94
K9.
KL.
M7N
MBDVC
P64
PKEHL
PQEST
PQUKI
PRINS
Q9U
RC3
SOI
7X8
5PM
ID FETCH-LOGICAL-c696t-13a59841f9bfc322bcafb33a0e8b42fd8d6c4dbe8671e081edd20906a5ffa5a13
IEDL.DBID P5Z
ISICitedReferencesCount 335
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000489784200052&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0028-0836
1476-4687
IngestDate Tue Nov 04 01:59:39 EST 2025
Sun Nov 09 13:03:35 EST 2025
Tue Oct 07 06:58:21 EDT 2025
Tue Nov 11 10:18:38 EST 2025
Sat Nov 29 11:29:53 EST 2025
Tue Jun 10 15:35:31 EDT 2025
Tue Nov 04 17:51:21 EST 2025
Thu Nov 13 14:41:25 EST 2025
Mon Jul 21 05:42:47 EDT 2025
Sat Nov 29 02:39:13 EST 2025
Tue Nov 18 22:20:34 EST 2025
Fri Feb 21 02:37:06 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7777
Language English
License Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c696t-13a59841f9bfc322bcafb33a0e8b42fd8d6c4dbe8671e081edd20906a5ffa5a13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC6858884
PMID 31578521
PQID 2306472652
PQPubID 40569
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6858884
proquest_miscellaneous_2300598827
proquest_journals_2306472652
gale_infotracmisc_A637083224
gale_infotracgeneralonefile_A637083224
gale_infotraccpiq_637083224
gale_infotracacademiconefile_A637083224
gale_incontextgauss_ISR_A637083224
pubmed_primary_31578521
crossref_citationtrail_10_1038_s41586_019_1607_3
crossref_primary_10_1038_s41586_019_1607_3
springer_journals_10_1038_s41586_019_1607_3
PublicationCentury 2000
PublicationDate 20191001
PublicationDateYYYYMMDD 2019-10-01
PublicationDate_xml – month: 10
  year: 2019
  text: 20191001
  day: 1
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationSubtitle International weekly journal of science
PublicationTitle Nature (London)
PublicationTitleAbbrev Nature
PublicationTitleAlternate Nature
PublicationYear 2019
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References (CR13) 2017; 169
Georgilis (CR21) 2018; 34
Olive, Banáth (CR28) 2006; 1
Wang (CR10) 2018; 28
Keng (CR19) 2009; 27
Flynn, Sayed, Sharma, Siddique, Pinato (CR22) 2019; 69
Peng, Golub, Sabatini (CR27) 2002; 22
Llovet (CR2) 2016; 2
Garcia Fortanet (CR23) 2016; 59
Koelzer (CR25) 2018; 73
Wang (CR4) 2017; 21
Koltun (CR11) 2012; 22
Dauch (CR16) 2016; 22
Faget, Ren, Stewart (CR15) 2019; 19
Llovet (CR3) 2008; 359
Zucman-Rossi, Villanueva, Nault, Llovet (CR7) 2015; 149
Rodrik-Outmezguine (CR6) 2011; 1
Fridman, Tainsky (CR14) 2008; 27
Evers (CR24) 2016; 34
Lin, Robert, Sukarieh, Michnick, Pelletier (CR18) 2010; 70
Montagnoli, Moll, Colotta (CR12) 2010; 16
Ogrodnik (CR9) 2017; 8
Bray (CR1) 2018; 68
Subramanian (CR26) 2005; 102
Eggert (CR17) 2016; 30
Chang (CR8) 2016; 22
Milanovic (CR20) 2018; 553
Sieben, Sturmlechner, van de Sluis, van Deursen (CR5) 2018; 28
J Zucman-Rossi (1607_CR7) 2015; 149
CJ Lin (1607_CR18) 2010; 70
M Ogrodnik (1607_CR9) 2017; 8
JM Llovet (1607_CR3) 2008; 359
A Montagnoli (1607_CR12) 2010; 16
Cancer Genome Atlas Research Network (1607_CR13) 2017; 169
J Chang (1607_CR8) 2016; 22
MJ Flynn (1607_CR22) 2019; 69
F Bray (1607_CR1) 2018; 68
DV Faget (1607_CR15) 2019; 19
VH Koelzer (1607_CR25) 2018; 73
B Evers (1607_CR24) 2016; 34
JM Llovet (1607_CR2) 2016; 2
ES Koltun (1607_CR11) 2012; 22
AL Fridman (1607_CR14) 2008; 27
A Georgilis (1607_CR21) 2018; 34
M Milanovic (1607_CR20) 2018; 553
J Garcia Fortanet (1607_CR23) 2016; 59
D Dauch (1607_CR16) 2016; 22
A Subramanian (1607_CR26) 2005; 102
C Wang (1607_CR10) 2018; 28
T Peng (1607_CR27) 2002; 22
L Wang (1607_CR4) 2017; 21
VS Rodrik-Outmezguine (1607_CR6) 2011; 1
PL Olive (1607_CR28) 2006; 1
T Eggert (1607_CR17) 2016; 30
CJ Sieben (1607_CR5) 2018; 28
VW Keng (1607_CR19) 2009; 27
31965074 - Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):135-136. doi: 10.1038/s41575-020-0262-3.
References_xml – volume: 22
  start-page: 3727
  year: 2012
  end-page: 3731
  ident: CR11
  article-title: Discovery of XL413, a potent and selective CDC7 inhibitor
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2012.04.024
– volume: 169
  start-page: 1327
  year: 2017
  end-page: 1341 e1323
  ident: CR13
  article-title: Comprehensive and integrative genomic characterization of hepatocellular carcinoma
  publication-title: Cell
  doi: 10.1016/j.cell.2017.05.046
– volume: 553
  start-page: 96
  year: 2018
  end-page: 100
  ident: CR20
  article-title: Senescence-associated reprogramming promotes cancer stemness
  publication-title: Nature
  doi: 10.1038/nature25167
– volume: 73
  start-page: 397
  year: 2018
  end-page: 406
  ident: CR25
  article-title: Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma
  publication-title: Histopathology
  doi: 10.1111/his.13528
– volume: 69
  start-page: 2258
  year: 2019
  end-page: 2270
  ident: CR22
  article-title: Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.30337
– volume: 30
  start-page: 533
  year: 2016
  end-page: 547
  ident: CR17
  article-title: Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.09.003
– volume: 68
  start-page: 394
  year: 2018
  end-page: 424
  ident: CR1
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
– volume: 149
  start-page: 1226
  year: 2015
  end-page: 1239.e1224
  ident: CR7
  article-title: Genetic landscape and biomarkers of hepatocellular carcinoma
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2015.05.061
– volume: 27
  start-page: 264
  year: 2009
  end-page: 274
  ident: CR19
  article-title: A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.1526
– volume: 359
  start-page: 378
  year: 2008
  end-page: 390
  ident: CR3
  article-title: Sorafenib in advanced hepatocellular carcinoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0708857
– volume: 34
  start-page: 631
  year: 2016
  end-page: 633
  ident: CR24
  article-title: CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.3536
– volume: 70
  start-page: 3199
  year: 2010
  end-page: 3208
  ident: CR18
  article-title: The antidepressant sertraline inhibits translation initiation by curtailing mammalian target of rapamycin signaling
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-09-4072
– volume: 27
  start-page: 5975
  year: 2008
  end-page: 5987
  ident: CR14
  article-title: Critical pathways in cellular senescence and immortalization revealed by gene expression profiling
  publication-title: Oncogene
  doi: 10.1038/onc.2008.213
– volume: 1
  start-page: 248
  year: 2011
  end-page: 259
  ident: CR6
  article-title: mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-11-0085
– volume: 16
  start-page: 4503
  year: 2010
  end-page: 4508
  ident: CR12
  article-title: Targeting cell division cycle 7 kinase: a new approach for cancer therapy
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-10-0185
– volume: 22
  start-page: 744
  year: 2016
  end-page: 753
  ident: CR16
  article-title: A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
  publication-title: Nat. Med.
  doi: 10.1038/nm.4107
– volume: 21
  start-page: 773
  year: 2017
  end-page: 783
  ident: CR4
  article-title: High-throughput functional genetic and compound screens identify targets for senescence induction in cancer
  publication-title: Cell Reports
  doi: 10.1016/j.celrep.2017.09.085
– volume: 1
  start-page: 23
  year: 2006
  end-page: 29
  ident: CR28
  article-title: The comet assay: a method to measure DNA damage in individual cells
  publication-title: Nat. Protocols
  doi: 10.1038/nprot.2006.5
– volume: 8
  year: 2017
  ident: CR9
  article-title: Cellular senescence drives age-dependent hepatic steatosis
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms15691
– volume: 102
  start-page: 15545
  year: 2005
  end-page: 15550
  ident: CR26
  article-title: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0506580102
– volume: 2
  start-page: 16018
  year: 2016
  ident: CR2
  article-title: Hepatocellular carcinoma
  publication-title: Nat. Rev. Dis. Primers
  doi: 10.1038/nrdp.2016.18
– volume: 22
  start-page: 78
  year: 2016
  end-page: 83
  ident: CR8
  article-title: Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
  publication-title: Nat. Med.
  doi: 10.1038/nm.4010
– volume: 28
  start-page: 690
  year: 2018
  end-page: 692
  ident: CR10
  article-title: A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma
  publication-title: Cell Res.
  doi: 10.1038/s41422-018-0020-z
– volume: 22
  start-page: 5575
  year: 2002
  end-page: 5584
  ident: CR27
  article-title: The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.22.15.5575-5584.2002
– volume: 28
  start-page: 723
  year: 2018
  end-page: 737
  ident: CR5
  article-title: Two-step senescence-focused cancer therapies
  publication-title: Trends Cell Biol.
  doi: 10.1016/j.tcb.2018.04.006
– volume: 19
  start-page: 439
  year: 2019
  end-page: 453
  ident: CR15
  article-title: Unmasking senescence: context-dependent effects of SASP in cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-019-0156-2
– volume: 34
  start-page: 85
  year: 2018
  end-page: 102.e109
  ident: CR21
  article-title: PTBP1-mediated alternative splicing regulates the inflammatory secretome and the pro-tumorigenic effects of senescent cells
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.06.007
– volume: 59
  start-page: 7773
  year: 2016
  end-page: 7782
  ident: CR23
  article-title: Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.6b00680
– volume: 553
  start-page: 96
  year: 2018
  ident: 1607_CR20
  publication-title: Nature
  doi: 10.1038/nature25167
– volume: 59
  start-page: 7773
  year: 2016
  ident: 1607_CR23
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.6b00680
– volume: 2
  start-page: 16018
  year: 2016
  ident: 1607_CR2
  publication-title: Nat. Rev. Dis. Primers
  doi: 10.1038/nrdp.2016.18
– volume: 22
  start-page: 5575
  year: 2002
  ident: 1607_CR27
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.22.15.5575-5584.2002
– volume: 1
  start-page: 248
  year: 2011
  ident: 1607_CR6
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-11-0085
– volume: 8
  year: 2017
  ident: 1607_CR9
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms15691
– volume: 1
  start-page: 23
  year: 2006
  ident: 1607_CR28
  publication-title: Nat. Protocols
  doi: 10.1038/nprot.2006.5
– volume: 359
  start-page: 378
  year: 2008
  ident: 1607_CR3
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0708857
– volume: 22
  start-page: 3727
  year: 2012
  ident: 1607_CR11
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2012.04.024
– volume: 16
  start-page: 4503
  year: 2010
  ident: 1607_CR12
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-10-0185
– volume: 28
  start-page: 690
  year: 2018
  ident: 1607_CR10
  publication-title: Cell Res.
  doi: 10.1038/s41422-018-0020-z
– volume: 102
  start-page: 15545
  year: 2005
  ident: 1607_CR26
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0506580102
– volume: 22
  start-page: 78
  year: 2016
  ident: 1607_CR8
  publication-title: Nat. Med.
  doi: 10.1038/nm.4010
– volume: 27
  start-page: 5975
  year: 2008
  ident: 1607_CR14
  publication-title: Oncogene
  doi: 10.1038/onc.2008.213
– volume: 70
  start-page: 3199
  year: 2010
  ident: 1607_CR18
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-09-4072
– volume: 149
  start-page: 1226
  year: 2015
  ident: 1607_CR7
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2015.05.061
– volume: 22
  start-page: 744
  year: 2016
  ident: 1607_CR16
  publication-title: Nat. Med.
  doi: 10.1038/nm.4107
– volume: 21
  start-page: 773
  year: 2017
  ident: 1607_CR4
  publication-title: Cell Reports
  doi: 10.1016/j.celrep.2017.09.085
– volume: 19
  start-page: 439
  year: 2019
  ident: 1607_CR15
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-019-0156-2
– volume: 28
  start-page: 723
  year: 2018
  ident: 1607_CR5
  publication-title: Trends Cell Biol.
  doi: 10.1016/j.tcb.2018.04.006
– volume: 73
  start-page: 397
  year: 2018
  ident: 1607_CR25
  publication-title: Histopathology
  doi: 10.1111/his.13528
– volume: 30
  start-page: 533
  year: 2016
  ident: 1607_CR17
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.09.003
– volume: 68
  start-page: 394
  year: 2018
  ident: 1607_CR1
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
– volume: 169
  start-page: 1327
  year: 2017
  ident: 1607_CR13
  publication-title: Cell
  doi: 10.1016/j.cell.2017.05.046
– volume: 69
  start-page: 2258
  year: 2019
  ident: 1607_CR22
  publication-title: Hepatology
  doi: 10.1002/hep.30337
– volume: 34
  start-page: 85
  year: 2018
  ident: 1607_CR21
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.06.007
– volume: 34
  start-page: 631
  year: 2016
  ident: 1607_CR24
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.3536
– volume: 27
  start-page: 264
  year: 2009
  ident: 1607_CR19
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.1526
– reference: 31965074 - Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):135-136. doi: 10.1038/s41575-020-0262-3.
SSID ssj0005174
Score 2.690022
Snippet Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies 1 , 2 ; broad-spectrum kinase inhibitors such as...
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies ; broad-spectrum kinase inhibitors such as sorafenib...
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies.sup.1,2; broad-spectrum kinase inhibitors such as...
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies; broad-spectrum kinase inhibitors such as sorafenib...
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies1,2; broad-spectrum kinase inhibitors such as sorafenib...
Liver cancer remains difficult to treat due to a paucity of drugs that target critical dependencies1,2 and broad spectrum kinase inhibitors like sorafenib...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 268
SubjectTerms 13
13/1
13/106
13/44
14
59
59/57
631/67/1059/602
631/67/68
Activation
Aging
Analysis
Animal models
Animals
Antidepressants
Apoptosis
Apoptosis - drug effects
Cancer therapies
Care and treatment
Cell Cycle Proteins - antagonists & inhibitors
Cell death
Cell Line, Tumor
Cellular Senescence - drug effects
Deoxyribonucleic acid
Disease Models, Animal
DNA
DNA biosynthesis
Female
Genetic screening
Hepatocellular carcinoma
Hepatocytes
Humanities and Social Sciences
Inhibitors
Kinases
Letter
Liver
Liver cancer
Liver Neoplasms - drug therapy
Liver Neoplasms - genetics
Liver Neoplasms - metabolism
Liver Neoplasms - pathology
Male
Mice
Mice, Inbred BALB C
Molecular Targeted Therapy
multidisciplinary
Mutation
Organic chemistry
p53 Protein
Physiological aspects
Protein Serine-Threonine Kinases - antagonists & inhibitors
Science
Science (multidisciplinary)
Senescence
Sertraline
Sertraline - pharmacology
Sertraline - therapeutic use
Signal transduction
Signal Transduction - drug effects
Signaling
TOR protein
TOR Serine-Threonine Kinases - antagonists & inhibitors
Tumor Suppressor Protein p53 - genetics
Tumors
Title Inducing and exploiting vulnerabilities for the treatment of liver cancer
URI https://link.springer.com/article/10.1038/s41586-019-1607-3
https://www.ncbi.nlm.nih.gov/pubmed/31578521
https://www.proquest.com/docview/2306472652
https://www.proquest.com/docview/2300598827
https://pubmed.ncbi.nlm.nih.gov/PMC6858884
Volume 574
WOSCitedRecordID wos000489784200052&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAQT
  databaseName: Nature
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: RNT
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://www.nature.com
  providerName: Nature Publishing
– providerCode: PRVPQU
  databaseName: Agricultural Science Database
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: M0K
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/agriculturejournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: M7P
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Earth, Atmospheric & Aquatic Science Database
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: PCBAR
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/eaasdb
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Engineering Database
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: M7S
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: http://search.proquest.com
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Environmental Science Database
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: PATMY
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/environmentalscience
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: 7X7
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Materials Science Database
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: KB.
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/materialsscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Nursing & Allied Health Database
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: 7RV
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/nahs
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest advanced technologies & aerospace journals
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: P5Z
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/hightechjournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: BENPR
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Psychology Database
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: M2M
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/psychology
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: 8C1
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Research Library
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: M2O
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Science Database (ProQuest)
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 20241207
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: M2P
  dateStart: 19880107
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/sciencejournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYBhIvwMZX2KgMQnwqLIkTx3lC3bSJabRU3Ya6vViOY49KVdo16_5-fI7bLhXshZeTIl9aO3c-n-NffofQOyLhqxhCfbN0xH6cQZmXLDeXEVUiEpSm2pK4_ki7XTYYZD33wq1ysMp5TLSBuhhLeEe-a1PlNKJJ9G1y5UPVKDhddSU01tAGsCTAxOwlF0uIxwoL8_xUk7DdyixcDPbSmQ8Uaz5prEur0fnW8rQKnVw5P7XL0uHj_x3QE_TIJaS4XXvQJrqnyi30wAJDZbWFNt3kr_BHx1D96Sk6goIf0vQHi7LACmB8Q4BP45vZCHQs4NZswbHJiLHJMPECzo7HGo8ACoIluNv0GTo7PDjd_-67mgy-pBmFyvUiyVgc6izX0gSDXAqdEyICxfI40gUrqIyLXAFtnjLphiqKKMgCKhKtRSJC8hytl-NSvUQ4VppmoTZeIc2eLCAiFlkkiGaSqSSOAw8Fc4tw6QjLoW7GiNuDc8J4bURujMjBiJx46PPilknN1nGX8lswMwcWjBJgNpdiVlX86KTP25SkAcS62EMfnJIemz-Xwn21YIYAxFkNze2GppwMr_it1veN1svaZH_7mZ2Gopntstk89ybuok3Fl67koTeLZrgTEHSlGs-sjsmkzX4q9dCL2ocXj4iEQHkUhR5KG969UAAO8mZLOfxtucihfAFjpltf5vNg2a1_PvlXdw9iGz2M7MQEyOQOWr-eztRrdF_eXA-raQutpf1fIAeplcxIth-20MbeQbfXN1fHe1-N7ATHIKOOlT-t7IFMa3nSssHC3Ndrn3bO_wC0rGGA
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aAwQvwMYtbIBB3FG01E4d5wGhCZhWrUxoDKlvxnHsUalKu2Yd4k_xG_FxknapYG974DHycRI75-ITf_4OwDOm8VQM46ELHXEYp1jmJc3cJeVGUcV5Yj2Jaz_Z3xeDQfplBX43Z2EQVtn4RO-o87HGf-RbfqmcUN6l7yfHIVaNwt3VpoRGpRZ75tdPl7KV73of3fd9TunOp8MPu2FdVSDUPOVYe111UxF3bJpZ7dQ508pmjKnIiCymNhc513GeGSR-My5gmjynURpx1bVWdVWHuftegsvOjycIIUsGyQJSssT63OyiMrFVukApMHdPQ6R0C1krDi5HgzPhcBmqubRf68Pgzs3_bQJvwY16wU22KwtZgxVTrMNVD3zV5Tqs1c6tJK9qBu7Xt6GHBU20Gz9RRU4MwhSHCA8np7MRynhA8dD1cSt-4lbQZA7XJ2NLRgh1IRrNaXoHvl3I4O7CajEuzH0gsbE87Vin9drlnBFTsUqpYlZoYbpxHAUQNRogdU3IjnVBRtIDA5iQldJIpzQSlUayAN7Mu0wqNpLzhJ-iWklk-SgQRnSkZmUpe18P5DZnSYS-PA7gZS1kx-7hWtWnMtwQkBisJbnRktST4bE80_qi1XpUfbK_3WazJei8mW43N9ora29ayoXqBvBk3ow9ESFYmPHMy7hMweWLSQD3KpuZTxHrIKUT7QSQtKxpLoAc6-2WYvjDc61jeQYh3Gu9bexu8Vr_nPkH5w_iMVzbPfzcl_3e_t4GXKfeKSA8dBNWT6Yz8xCu6NOTYTl95N0Lge8XbY5_AM_Ts1Q
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4a4yJegI1b2ACDuKOoaZyL84DQxKioNlUVA2nixTiOPSpVadesQ_w1fh3n5NIuFextDzxWPk5j-1x84s_fAXjGNd2K4ZGLoSNwg4TKvCQp_vQjo3wVRbEtSVz348FAHB4mwzX43dyFIVhl4xNLR51NNH0j75Rb5diPQr9ja1jEcLf3fnrsUgUpOmltymlUKrJnfv3E9K1419_FtX7u-72PXz58cusKA66OkojqsKswEUHXJqnVqNqpVjblXHlGpIFvM5FFOshSQyRwBoOnyTLfS7xIhdaqUHU5PvcSXI4xx6TEbxh-W8JLVhigmxNVLjoFBk1BeXziEr2by1sxcTUynAmNq7DNlbPbMiT2bv7Pk3kLbtQbcbZTWc4GrJl8E66WgFhdbMJG7fQK9qpm5n59G_pU6ETjXDCVZ8wQfHFEsHF2Oh-TTAk0HmEfzAQY7qzZAsbPJpaNCQLDNJnZ7A58vZDB3YX1fJKb-8ACY6Oka9EaNOaiHleBSnzFrdDChEHgOeA12iB1TdRO9ULGsgQMcCErBZKoQJIUSHIH3iy6TCuWkvOEn5KKSWL_yGnpj9S8KGT_4LPciXjskY8PHHhZC9kJ_rlW9W0NHAIRhrUkt1qSejo6lmdaX7Raj6ol-9tjtluC6OV0u7nRZFl72UIu1diBJ4tm6knIwdxM5qUMZhCYR8YO3KvsZzFFvEtUT37XgbhlWQsB4l5vt-SjHyUHO5VtEAJf621jg8vX-ufMPzh_EI_hGlqh3O8P9rbgul_6B0KNbsP6yWxuHsIVfXoyKmaPSk_D4PtFW-MfeGq8Rw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inducing+and+exploiting+vulnerabilities+for+the+treatment+of+liver+cancer&rft.jtitle=Nature+%28London%29&rft.au=Wang%2C+Cun&rft.au=Vegna%2C+Serena&rft.au=Jin%2C+Haojie&rft.au=Benedict%2C+Bente&rft.date=2019-10-01&rft.issn=0028-0836&rft.eissn=1476-4687&rft.volume=574&rft.issue=7777&rft.spage=268&rft.epage=272&rft_id=info:doi/10.1038%2Fs41586-019-1607-3&rft_id=info%3Apmid%2F31578521&rft.externalDocID=PMC6858884
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-0836&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-0836&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-0836&client=summon